Loureirin A is a narrow-spectrum antimicrobial agent against Helicobacter pylori
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00314-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Qian Tong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathogen Biology, Jiangsu Key Laboratory of Pathogen Biology, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Helicobacter pylori, Helicobacter Infections, Omeprazole, Microbial Sensitivity Tests. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), MOST | National Key Research and Development Program of China (NKPs).
Abstract (Originalsprache)
Currently, Helicobacter pylori eradication by antibiotic therapy faces various challenges, including antibiotic resistance, side effects on intestinal commensal bacteria, and patient compliance. In this study, loureirin A (LrA), a traditional Chinese medicine monomer extracted from Sanguis Draconis flavones, was found to possess specific antibacterial activity against H. pylori without the bacteria displaying a tendency to develop resistance in vitro . LrA demonstrated a synergistic or additive effect when combined with omeprazole (a proton pump inhibitor) against H. pylori . The combination of LrA and omeprazole showed promising anti- H . pylori potential, exhibiting notable in vivo efficacy comparable to standard triple therapy in mouse models infected with both drug-sensitive and drug-resistant H. pylori strains. Moreover, the narrow-spectrum antibacterial profile of LrA is reflected in its minimal effect on the diversity and composition of the mouse gut microbiota. The underlying mechanism of action of LrA against H. pylori involves the generation of bactericidal levels of reactive oxygen species, resulting in apoptosis-like cell death. These findings indicate that LrA is a promising lead compound targeting H. pylori without harming the commensal bacteria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathogen Biology, Jiangsu Key Laboratory of Pathogen Biology, Nanjing Medical University, Nanjing, China.
- Helicobacter pylori Research Center, Nanjing Medical University, Nanjing, China.
- Department of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
ORCID-Profile: Hongkai Bi
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- MOST | National Key Research and Development Program of China (NKPs)
Zitieren
APA
Tong, Q., Yin, C., Hang, X., Bai, Y., Zhang, C., Xu, J., Huang, Y., Ge, Y., Chen, T., Zeng, L., Jia, J., & Bi, H. (2024). Loureirin A is a narrow-spectrum antimicrobial agent against Helicobacter pylori. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00314-24
Vancouver
Tong Q, Yin C, Hang X, Bai Y, Zhang C, Xu J, et al. Loureirin A is a narrow-spectrum antimicrobial agent against Helicobacter pylori. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00314-24
BibTeX
@article{Tong2024,
author = {Tong, Qian and Yin, Chengqiang and Hang, Xudong and Bai, Yuefan and Zhang, Chongwen and Xu, Jingcheng and Huang, Yan and Ge, Yixin and Chen, Tianyu and Zeng, Liping and Jia, Jia and Bi, Hongkai},
title = {Loureirin A is a narrow-spectrum antimicrobial agent against Helicobacter pylori},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00314-24}
}
EUVIMED